Towards a scalable bioprocess for rAAV production using a HeLa stable cell line

Bibliographic Details
Main Author: Escandell, José
Publication Date: 2023
Other Authors: Moura, Filipa, Carvalho, Sofia B., Silva, Ricardo J.S., Correia, Ricardo, Roldão, Antonio, Gomes-Alves, Patrícia, Alves, Paula M.
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10362/165687
Summary: Funding Information: We thank Dr. Maria João Sebastião, Dr. Mafalda Dias, Maria Gonçalves and Mariana Antunes for their helpful discussion and experimental support. This work was funded by Fundação para a Ciência e Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES, Portugal) through national funds to iNOVA4Health (UIDB/04462/2020 and UIDP/04462/2020), the Associate Laboratory LS4FUTURE (LA/P/0087/2020) and project PTDC/BTM-ORG/1383/2020, and by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 813453 and TRANSVAC2 No. 730964; J.M.E. is funded by Stimulus of Scientific Employment, Individual Support program (2020.01216.CEECIND) from FCT; F.M is funded by PhD fellowship (2022.11494.BD) from FCT. Images were generated with Biorender.com. Funding Information: We thank Dr. Maria João Sebastião, Dr. Mafalda Dias, Maria Gonçalves and Mariana Antunes for their helpful discussion and experimental support. This work was funded by Fundação para a Ciência e Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES, Portugal) through national funds to iNOVA4Health (UIDB/04462/2020 and UIDP/04462/2020), the Associate Laboratory LS4FUTURE (LA/P/0087/2020) and project PTDC/BTM‐ORG/1383/2020, and by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska‐Curie grant agreement No. 813453 and TRANSVAC2 No. 813453; J.M.E. is funded by Stimulus of Scientific Employment, Individual Support program (2020.01216.CEECIND) from FCT; F.M is funded by PhD fellowship (2022.11494.BD) from FCT. Images were generated with Biorender.com . Publisher Copyright: © 2023 The Authors. Biotechnology and Bioengineering published by Wiley Periodicals LLC.
id RCAP_c9db277908c5d2ed4a7962dbf1ce6cc9
oai_identifier_str oai:run.unl.pt:10362/165687
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Towards a scalable bioprocess for rAAV production using a HeLa stable cell linebioprocess developmentcell line developmentdownstream processinggene therapyHeLaS3recombinant adeno-associated viruses (rAAV)stable cell lineBiotechnologyBioengineeringApplied Microbiology and BiotechnologyFunding Information: We thank Dr. Maria João Sebastião, Dr. Mafalda Dias, Maria Gonçalves and Mariana Antunes for their helpful discussion and experimental support. This work was funded by Fundação para a Ciência e Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES, Portugal) through national funds to iNOVA4Health (UIDB/04462/2020 and UIDP/04462/2020), the Associate Laboratory LS4FUTURE (LA/P/0087/2020) and project PTDC/BTM-ORG/1383/2020, and by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 813453 and TRANSVAC2 No. 730964; J.M.E. is funded by Stimulus of Scientific Employment, Individual Support program (2020.01216.CEECIND) from FCT; F.M is funded by PhD fellowship (2022.11494.BD) from FCT. Images were generated with Biorender.com. Funding Information: We thank Dr. Maria João Sebastião, Dr. Mafalda Dias, Maria Gonçalves and Mariana Antunes for their helpful discussion and experimental support. This work was funded by Fundação para a Ciência e Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES, Portugal) through national funds to iNOVA4Health (UIDB/04462/2020 and UIDP/04462/2020), the Associate Laboratory LS4FUTURE (LA/P/0087/2020) and project PTDC/BTM‐ORG/1383/2020, and by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska‐Curie grant agreement No. 813453 and TRANSVAC2 No. 813453; J.M.E. is funded by Stimulus of Scientific Employment, Individual Support program (2020.01216.CEECIND) from FCT; F.M is funded by PhD fellowship (2022.11494.BD) from FCT. Images were generated with Biorender.com . Publisher Copyright: © 2023 The Authors. Biotechnology and Bioengineering published by Wiley Periodicals LLC.The majority of recombinant adeno-associated viruses (rAAV) approved for clinical use or in clinical trials areproduced by transient transfection using the HEK293 cell line. However, this platform has several manufacturing bottlenecks at commercial scales namely, low product quality (full to empty capsid ratio <20% in most rAAV serotypes), lower productivities obtained after scale-up and the high cost of raw materials, in particular of Good Manufacturing Practice grade plasmid DNA required for transfection. The HeLa-based stable cell line rAAV production system provides a robust and scalable alternative to transient transfection systems. Nevertheless, the time required to generate the producer cell lines combined with the complexity of rAAV production and purification processes still pose several barriers to the use of this platform as a suitable alternative to the HEK293 transient transfection. In this work we streamlined the cell line development and bioprocessing for the HeLaS3-based production of rAAV. By exploring this optimized approach, producer cell lines were generated in 3-4 months, and presented rAAV2 volumetric production (bulk) > 3 × 1011 vg/mL and full to empty capsids ratio (>70%) at 2 L bioreactor scale. Moreover, the established downstream process, based on ion exchange and affinity-based chromatography, efficiently eliminated process related impurities, including the Adenovirus 5 helper virus required for production with a log reduction value of 9. Overall, we developed a time-efficient and robust rAAV bioprocess using a stable producer cell line achieving purified rAAV2 yields > 1 × 1011 vg/mL. This optimized platform may address manufacturing challenges for rAAV based medicines.Instituto de Tecnologia Química e Biológica António Xavier (ITQB)RUNEscandell, JoséMoura, FilipaCarvalho, Sofia B.Silva, Ricardo J.S.Correia, RicardoRoldão, AntonioGomes-Alves, PatríciaAlves, Paula M.2024-04-01T23:17:45Z2023-092023-09-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article10application/pdfhttp://hdl.handle.net/10362/165687eng0006-3592PURE: 73157781https://doi.org/10.1002/bit.28394info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-05-22T18:20:05Zoai:run.unl.pt:10362/165687Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T17:50:50.825143Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Towards a scalable bioprocess for rAAV production using a HeLa stable cell line
title Towards a scalable bioprocess for rAAV production using a HeLa stable cell line
spellingShingle Towards a scalable bioprocess for rAAV production using a HeLa stable cell line
Escandell, José
bioprocess development
cell line development
downstream processing
gene therapy
HeLaS3
recombinant adeno-associated viruses (rAAV)
stable cell line
Biotechnology
Bioengineering
Applied Microbiology and Biotechnology
title_short Towards a scalable bioprocess for rAAV production using a HeLa stable cell line
title_full Towards a scalable bioprocess for rAAV production using a HeLa stable cell line
title_fullStr Towards a scalable bioprocess for rAAV production using a HeLa stable cell line
title_full_unstemmed Towards a scalable bioprocess for rAAV production using a HeLa stable cell line
title_sort Towards a scalable bioprocess for rAAV production using a HeLa stable cell line
author Escandell, José
author_facet Escandell, José
Moura, Filipa
Carvalho, Sofia B.
Silva, Ricardo J.S.
Correia, Ricardo
Roldão, Antonio
Gomes-Alves, Patrícia
Alves, Paula M.
author_role author
author2 Moura, Filipa
Carvalho, Sofia B.
Silva, Ricardo J.S.
Correia, Ricardo
Roldão, Antonio
Gomes-Alves, Patrícia
Alves, Paula M.
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Instituto de Tecnologia Química e Biológica António Xavier (ITQB)
RUN
dc.contributor.author.fl_str_mv Escandell, José
Moura, Filipa
Carvalho, Sofia B.
Silva, Ricardo J.S.
Correia, Ricardo
Roldão, Antonio
Gomes-Alves, Patrícia
Alves, Paula M.
dc.subject.por.fl_str_mv bioprocess development
cell line development
downstream processing
gene therapy
HeLaS3
recombinant adeno-associated viruses (rAAV)
stable cell line
Biotechnology
Bioengineering
Applied Microbiology and Biotechnology
topic bioprocess development
cell line development
downstream processing
gene therapy
HeLaS3
recombinant adeno-associated viruses (rAAV)
stable cell line
Biotechnology
Bioengineering
Applied Microbiology and Biotechnology
description Funding Information: We thank Dr. Maria João Sebastião, Dr. Mafalda Dias, Maria Gonçalves and Mariana Antunes for their helpful discussion and experimental support. This work was funded by Fundação para a Ciência e Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES, Portugal) through national funds to iNOVA4Health (UIDB/04462/2020 and UIDP/04462/2020), the Associate Laboratory LS4FUTURE (LA/P/0087/2020) and project PTDC/BTM-ORG/1383/2020, and by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 813453 and TRANSVAC2 No. 730964; J.M.E. is funded by Stimulus of Scientific Employment, Individual Support program (2020.01216.CEECIND) from FCT; F.M is funded by PhD fellowship (2022.11494.BD) from FCT. Images were generated with Biorender.com. Funding Information: We thank Dr. Maria João Sebastião, Dr. Mafalda Dias, Maria Gonçalves and Mariana Antunes for their helpful discussion and experimental support. This work was funded by Fundação para a Ciência e Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES, Portugal) through national funds to iNOVA4Health (UIDB/04462/2020 and UIDP/04462/2020), the Associate Laboratory LS4FUTURE (LA/P/0087/2020) and project PTDC/BTM‐ORG/1383/2020, and by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska‐Curie grant agreement No. 813453 and TRANSVAC2 No. 813453; J.M.E. is funded by Stimulus of Scientific Employment, Individual Support program (2020.01216.CEECIND) from FCT; F.M is funded by PhD fellowship (2022.11494.BD) from FCT. Images were generated with Biorender.com . Publisher Copyright: © 2023 The Authors. Biotechnology and Bioengineering published by Wiley Periodicals LLC.
publishDate 2023
dc.date.none.fl_str_mv 2023-09
2023-09-01T00:00:00Z
2024-04-01T23:17:45Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/165687
url http://hdl.handle.net/10362/165687
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 0006-3592
PURE: 73157781
https://doi.org/10.1002/bit.28394
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 10
application/pdf
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833597007602647040